EN3835
Phase 3Biologic
Endo PharmaceuticalsEN3835 is one of 43 biologic programs targeting Uterine leiomyoma. It is currently in Phase 3.
3
Indications
9
Total Trials
0
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
35 competitors in Frozen Shoulder
#DrugCompanyPhaseTrials
1Medrol
PfizerApproved
Elavil
AstraZenecaApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Rayos
RRoxane Laboratories
Approved
Aspercreme Warming
AAveritas Pharma, Inc.
Approved
Xylocaine
MMEDRx USA, Inc.
Approved
Decadron
AAspen Global Incorporated
Approved
Compound Betamethasone
SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Approved
Kenalog
BBausch Health Americas, Inc.
Phase 3
AMPHADASE
AAmphastar Pharmaceuticals, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Fibromatosis3 trials
Effectiveness2 trials
Uterine leiomyoma1 trial
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for EN3835. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company